These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11734262)

  • 1. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Bostom AG
    Lancet; 2001 Nov; 358(9295):1811-2. PubMed ID: 11734262
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Chan NN; Chow FC
    Lancet; 2001 Nov; 358(9295):1811; author reply 1811-2. PubMed ID: 11734263
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.
    Corbelli JC; Bullano MF; Willey VJ; Cziraky MJ; Corbelli ME; Waugh W
    Am J Cardiol; 2002 Dec; 90(12):1388-91. PubMed ID: 12480052
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of fenofibrate and gemfibrozil on plasma homocysteine.
    Westphal S; Dierkes J; Luley C
    Lancet; 2001 Jul; 358(9275):39-40. PubMed ID: 11454380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering drugs and homocysteine.
    de Lorgeril M; Salen P; Paillard F; Lacan P; Richard G
    Lancet; 1999 Jan; 353(9148):209-10. PubMed ID: 9923885
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: a single-blind, randomized, and cross-over study.
    Jen SL; Chen JW; Lee WL; Wang SP
    Zhonghua Yi Xue Za Zhi (Taipei); 1997 Apr; 59(4):217-24. PubMed ID: 9216117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication of fibrate therapy for homocysteine.
    Goffin E; Jamar F; Desager JP; Devuyst O
    Lancet; 1999 Oct; 354(9185):1209. PubMed ID: 10513738
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C.
    Ncube V; Starkey B; Wang T
    Ann Clin Biochem; 2012 Sep; 49(Pt 5):491-3. PubMed ID: 22829698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrates and homocysteine.
    Young IS; Woodside JV
    Nutrition; 2001; 17(11-12):973-4. PubMed ID: 11744353
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Bortolini M; Salko T; Freudenreich MO; Isaacsohn JL; Troendle AJ; Gonasun L
    Am J Cardiol; 2003 Jan; 91(2):238-40. PubMed ID: 12521642
    [No Abstract]   [Full Text] [Related]  

  • 11. Fenofibrate: altered renal function.
    Prescrire Int; 2011 Jun; 20(117):154-5. PubMed ID: 21682015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
    Dierkes J; Westphal S; Kunstmann S; Banditt P; Lössner A; Luley C
    Atherosclerosis; 2001 Sep; 158(1):161-4. PubMed ID: 11500187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate, homocysteine and renal function.
    Foucher C; Brugère L; Ansquer JC
    Curr Vasc Pharmacol; 2010 Sep; 8(5):589-603. PubMed ID: 20507276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].
    Dobordzhginidze LM
    Kardiologiia; 2004; 44(3):87-93. PubMed ID: 15489838
    [No Abstract]   [Full Text] [Related]  

  • 15. [Helsinki Heart Study].
    Sekiya M; Ishibashi S
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():404-9. PubMed ID: 11347103
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential involvement of PPAR α activation in diminishing the hepatoprotective effect of fenofibrate in NAFLD: Accuracy of non- invasive panel in determining the stage of liver fibrosis in rats.
    Hamed AM; El-Kharashi OA; Boctor SS; Abd-Elaziz LF
    Biomed Pharmacother; 2017 Jan; 85():68-78. PubMed ID: 27930988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology department: pharmacologic approaches to abnormal blood lipids.
    Gylys KH
    J Cardiovasc Nurs; 2000 Jan; 14(2):9-15. PubMed ID: 10653272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.
    Packard KA; Backes JM; Lenz TL; Wurdeman RL; Destache C; Hilleman DE
    Pharmacotherapy; 2002 Dec; 22(12):1527-32. PubMed ID: 12495163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum homocysteine increases after therapy with fenofibrate or bezafibrate.
    Dierkes J; Westphal S; Luley C
    Lancet; 1999 Jul; 354(9174):219-20. PubMed ID: 10421307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate-Induced elevation in serum creatinine.
    Ritter JL; Nabulsi S
    Pharmacotherapy; 2001 Sep; 21(9):1145-9. PubMed ID: 11560205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.